Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers.

Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR.

Mol Cancer Res. 2019 May;17(5):1036-1048. doi: 10.1158/1541-7786.MCR-18-1026. Epub 2019 Feb 7.

PMID:
30733375
2.

Isoxazolo[3,4-d]pyridazinones positively modulate the metabotropic glutamate subtypes 2 and 4.

Gates C, Backos DS, Reigan P, Kang HJ, Koerner C, Mirzaei J, Natale NR.

Bioorg Med Chem. 2018 Sep 15;26(17):4797-4803. doi: 10.1016/j.bmc.2018.08.012. Epub 2018 Aug 10.

3.

Development of Potent Pyrazolopyrimidinone-Based WEE1 Inhibitors with Limited Single-Agent Cytotoxicity for Cancer Therapy.

Matheson CJ, Casalvieri KA, Backos DS, Reigan P.

ChemMedChem. 2018 Aug 20;13(16):1681-1694. doi: 10.1002/cmdc.201800188. Epub 2018 Jul 11.

4.

Selective Targeting of RSK Isoforms in Cancer.

Casalvieri KA, Matheson CJ, Backos DS, Reigan P.

Trends Cancer. 2017 Apr;3(4):302-312. doi: 10.1016/j.trecan.2017.03.004. Epub 2017 Apr 3. Review.

PMID:
28718440
5.

Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter.

Steiger SA, Li C, Backos DS, Reigan P, Natale NR.

Bioorg Med Chem. 2017 Jun 15;25(12):3223-3234. doi: 10.1016/j.bmc.2017.04.008. Epub 2017 Apr 8.

6.

Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors.

Furtek SL, Matheson CJ, Backos DS, Reigan P.

Oncotarget. 2016 Nov 22;7(47):77998-78008. doi: 10.18632/oncotarget.12868.

7.

Targeting WEE1 Kinase in Cancer.

Matheson CJ, Backos DS, Reigan P.

Trends Pharmacol Sci. 2016 Oct;37(10):872-881. doi: 10.1016/j.tips.2016.06.006. Epub 2016 Jul 14. Review.

PMID:
27427153
8.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.

Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P.

ACS Chem Biol. 2016 Jul 15;11(7):2066-7. doi: 10.1021/acschembio.6b00466. Epub 2016 Jun 15. No abstract available.

PMID:
27304454
9.

A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells.

Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P.

ACS Chem Biol. 2016 Apr 15;11(4):921-30. doi: 10.1021/acschembio.5b00725. Epub 2016 Jan 8. Erratum in: ACS Chem Biol. 2016 Jul 15;11(7):2066-7.

PMID:
26745241
10.

Strategies and Approaches of Targeting STAT3 for Cancer Treatment.

Furtek SL, Backos DS, Matheson CJ, Reigan P.

ACS Chem Biol. 2016 Feb 19;11(2):308-18. doi: 10.1021/acschembio.5b00945. Epub 2016 Jan 15. Review.

PMID:
26730496
11.

Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors.

Xiong W, Matheson CJ, Xu M, Backos DS, Mills TS, Salian-Mehta S, Kiseljak-Vassiliades K, Reigan P, Wierman ME.

Mol Cancer Ther. 2016 Mar;15(3):412-20. doi: 10.1158/1535-7163.MCT-15-0703. Epub 2015 Dec 31.

12.

RSK3: A regulator of pathological cardiac remodeling.

Martinez EC, Passariello CL, Li J, Matheson CJ, Dodge-Kafka K, Reigan P, Kapiloff MS.

IUBMB Life. 2015 May;67(5):331-7. doi: 10.1002/iub.1383. Epub 2015 May 19. Review.

13.

Interleukin-6/STAT3 Pathway Signaling Drives an Inflammatory Phenotype in Group A Ependymoma.

Griesinger AM, Josephson RJ, Donson AM, Mulcahy Levy JM, Amani V, Birks DK, Hoffman LM, Furtek SL, Reigan P, Handler MH, Vibhakar R, Foreman NK.

Cancer Immunol Res. 2015 Oct;3(10):1165-74. doi: 10.1158/2326-6066.CIR-15-0061. Epub 2015 May 12.

14.

AIMing towards improved antitumor efficacy.

Weaver MJ, Kearns AK, Stump S, Li C, Gajewski MP, Rider KC, Backos DS, Reigan PR, Beall HD, Natale NR.

Bioorg Med Chem Lett. 2015 Apr 15;25(8):1765-1770. doi: 10.1016/j.bmcl.2015.02.063. Epub 2015 Mar 3.

15.

Human ALDH1B1 polymorphisms may affect the metabolism of acetaldehyde and all-trans retinaldehyde--in vitro studies and computational modeling.

Jackson BC, Reigan P, Miller B, Thompson DC, Vasiliou V.

Pharm Res. 2015 May;32(5):1648-62. doi: 10.1007/s11095-014-1564-3. Epub 2014 Nov 21.

16.

Oxidative stress-mediated aldehyde adduction of GRP78 in a mouse model of alcoholic liver disease: functional independence of ATPase activity and chaperone function.

Galligan JJ, Fritz KS, Backos DS, Shearn CT, Smathers RL, Jiang H, MacLean KN, Reigan PR, Petersen DR.

Free Radic Biol Med. 2014 Aug;73:411-20. doi: 10.1016/j.freeradbiomed.2014.06.002. Epub 2014 Jun 9.

17.

Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration.

Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, Southall N, Reigan P, Marugan J, Ford HL, Zhao R.

J Biol Chem. 2014 Jun 6;289(23):16349-61. doi: 10.1074/jbc.M114.566729. Epub 2014 Apr 22.

18.

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.

Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R.

Mol Cancer. 2014 Mar 24;13:72. doi: 10.1186/1476-4598-13-72.

19.

Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.

Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC.

Mol Cancer Ther. 2013 Dec;12(12):2675-84. doi: 10.1158/1535-7163.MCT-13-0424. Epub 2013 Oct 11.

20.

Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis.

Shearn CT, Smathers RL, Backos DS, Reigan P, Orlicky DJ, Petersen DR.

Free Radic Biol Med. 2013 Dec;65:680-692. doi: 10.1016/j.freeradbiomed.2013.07.011. Epub 2013 Jul 17.

21.

Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma.

Backos DS, Fritz KS, McArthur DG, Kepa JK, Donson AM, Petersen DR, Foreman NK, Franklin CC, Reigan P.

Neurochem Res. 2013 Sep;38(9):1838-49. doi: 10.1007/s11064-013-1090-4. Epub 2013 Jun 7.

PMID:
23743623
22.

Identification of functionally relevant lysine residues that modulate human farnesoid X receptor activation.

Sun AQ, Luo Y, Backos DS, Xu S, Balasubramaniyan N, Reigan P, Suchy FJ.

Mol Pharmacol. 2013 May;83(5):1078-86. doi: 10.1124/mol.113.084772. Epub 2013 Mar 5.

23.

ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1.

Vasiliou V, Sandoval M, Backos DS, Jackson BC, Chen Y, Reigan P, Lanaspa MA, Johnson RJ, Koppaka V, Thompson DC.

Chem Biol Interact. 2013 Feb 25;202(1-3):22-31. doi: 10.1016/j.cbi.2012.12.018. Epub 2013 Jan 21.

24.

Comparative genomics, molecular evolution and computational modeling of ALDH1B1 and ALDH2.

Jackson BC, Holmes RS, Backos DS, Reigan P, Thompson DC, Vasiliou V.

Chem Biol Interact. 2013 Feb 25;202(1-3):11-21. doi: 10.1016/j.cbi.2012.11.022. Epub 2012 Dec 13.

25.

Post-translational oxidative modification and inactivation of mitochondrial complex I in epileptogenesis.

Ryan K, Backos DS, Reigan P, Patel M.

J Neurosci. 2012 Aug 15;32(33):11250-8. doi: 10.1523/JNEUROSCI.0907-12.2012.

26.

Manganese superoxide dismutase regulates a metabolic switch during the mammalian cell cycle.

Sarsour EH, Kalen AL, Xiao Z, Veenstra TD, Chaudhuri L, Venkataraman S, Reigan P, Buettner GR, Goswami PC.

Cancer Res. 2012 Aug 1;72(15):3807-16. doi: 10.1158/0008-5472.CAN-11-1063. Epub 2012 Jun 18.

27.

Characterization of 4-HNE modified L-FABP reveals alterations in structural and functional dynamics.

Smathers RL, Fritz KS, Galligan JJ, Shearn CT, Reigan P, Marks MJ, Petersen DR.

PLoS One. 2012;7(6):e38459. doi: 10.1371/journal.pone.0038459. Epub 2012 Jun 6.

28.
29.

Neoamphimedine circumvents metnase-enhanced DNA topoisomerase II╬▒ activity through ATP-competitive inhibition.

Ponder J, Yoo BH, Abraham AD, Li Q, Ashley AK, Amerin CL, Zhou Q, Reid BG, Reigan P, Hromas R, Nickoloff JA, LaBarbera DV.

Mar Drugs. 2011;9(11):2397-408. doi: 10.3390/md9112397. Epub 2011 Nov 18.

30.

The role of glutathione in brain tumor drug resistance.

Backos DS, Franklin CC, Reigan P.

Biochem Pharmacol. 2012 Apr 15;83(8):1005-12. doi: 10.1016/j.bcp.2011.11.016. Epub 2011 Nov 28. Review.

PMID:
22138445
31.

Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems.

Yan C, Dufour M, Siegel D, Reigan P, Gomez J, Shieh B, Moody CJ, Ross D.

Biochemistry. 2011 Aug 9;50(31):6678-88. doi: 10.1021/bi2002967. Epub 2011 Jul 19.

32.

Determinants of adipophilin function in milk lipid formation and secretion.

Chong BM, Reigan P, Mayle-Combs KD, Orlicky DJ, McManaman JL.

Trends Endocrinol Metab. 2011 Jun;22(6):211-7. doi: 10.1016/j.tem.2011.04.003. Epub 2011 May 17. Review.

33.

Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.

Dufour M, Yan C, Siegel D, Colucci MA, Jenner M, Oldham NJ, Gomez J, Reigan P, Li Y, De Matteis CI, Ross D, Moody CJ.

Chembiochem. 2011 May 16;12(8):1203-8. doi: 10.1002/cbic.201100085. Epub 2011 Apr 19.

34.

4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification.

Fritz KS, Galligan JJ, Smathers RL, Roede JR, Shearn CT, Reigan P, Petersen DR.

Chem Res Toxicol. 2011 May 16;24(5):651-62. doi: 10.1021/tx100355a. Epub 2011 Apr 14.

35.

Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells.

Shearn CT, Fritz KS, Reigan P, Petersen DR.

Biochemistry. 2011 May 17;50(19):3984-96. doi: 10.1021/bi200029w. Epub 2011 Apr 20.

PMID:
21438592
36.

The adipophilin C terminus is a self-folding membrane-binding domain that is important for milk lipid secretion.

Chong BM, Russell TD, Schaack J, Orlicky DJ, Reigan P, Ladinsky M, McManaman JL.

J Biol Chem. 2011 Jul 1;286(26):23254-65. doi: 10.1074/jbc.M110.217091. Epub 2011 Mar 7.

37.

A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins.

Reigan P, Siegel D, Guo W, Ross D.

Mol Pharmacol. 2011 May;79(5):823-32. doi: 10.1124/mol.110.070086. Epub 2011 Feb 1.

38.

In vitro and in silico characterization of peroxiredoxin 6 modified by 4-hydroxynonenal and 4-oxononenal.

Roede JR, Carbone DL, Doorn JA, Kirichenko OV, Reigan P, Petersen DR.

Chem Res Toxicol. 2008 Dec;21(12):2289-99. doi: 10.1021/tx800244u.

PMID:
19548352
39.

Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target.

Yan C, Shieh B, Reigan P, Zhang Z, Colucci MA, Chilloux A, Newsome JJ, Siegel D, Chan D, Moody CJ, Ross D.

Mol Pharmacol. 2009 Jul;76(1):163-72. doi: 10.1124/mol.109.055855. Epub 2009 Apr 13.

40.

Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action.

Guo W, Reigan P, Siegel D, Ross D.

Drug Metab Dispos. 2008 Oct;36(10):2050-7. doi: 10.1124/dmd.108.022004. Epub 2008 Jul 17.

41.

Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity.

Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, Moody CJ.

J Med Chem. 2007 Nov 15;50(23):5780-9. Epub 2007 Oct 18.

42.

Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.

Reigan P, Gbaj A, Stratford IJ, Bryce RA, Freeman S.

Eur J Med Chem. 2008 Jun;43(6):1248-60. Epub 2007 Aug 6.

PMID:
17870212
43.

Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain.

Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, Harvey J, Freed BM.

J Biol Chem. 2007 Jul 6;282(27):19666-75. Epub 2007 May 9.

44.
45.

Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.

Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW Jr, Wang PG, Sun D.

J Med Chem. 2006 Oct 19;49(21):6290-7.

47.

The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins.

Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D.

Mol Pharmacol. 2006 Oct;70(4):1194-203. Epub 2006 Jul 6.

PMID:
16825487
48.

Thymidine phosphorylase from Escherichia coli: tight-binding inhibitors as enzyme active-site titrants.

Gbaj A, Edwards PN, Reigan P, Freeman S, Jaffar M, Douglas KT.

J Enzyme Inhib Med Chem. 2006 Feb;21(1):69-73.

PMID:
16570508
49.
50.

Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs.

Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S.

J Med Chem. 2005 Jan 27;48(2):392-402.

PMID:
15658853

Supplemental Content

Loading ...
Support Center